SEC Company Response from Lexaria Bioscience Corp. (LEXX) (CIK 0001348362) (LEXX) — Jun 7, 2024
Lexaria Bioscience Corp. (LEXX) (CIK 0001348362)
Date: June 7, 2024 · CIK: 0001348362 · Accession: 0001640334-24-000923
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-279909
Letter
lxrp_corresp.htm
June 7, 2024
VIA EDGAR AND FACSIMILE
United States Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F. Street, N.E.
Washington, D.C. 20549
Attention: Tamika Sheppard
Re:
Lexaria Bioscience Corp. (the “Company”)
Registration Statement on Form S-1
File No. 333-279909
Ladies and Gentlemen:
In accordance with Rule 461 under the Securities Act of 1933, as amended, the undersigned respectfully requests that the effective date for the Registration Statement referred to above be accelerated so that it will be declared effective at 4:30PM EDT on Tuesday, June 11, 2024, or as soon thereafter as is practicable.
If you have any questions, please call Avital Perlman at 212-930-9700.
Very truly yours,
LEXARIA BIOSCIENCE CORP.
Show Raw Text
CORRESP
1
filename1.htm
lxrp_corresp.htm
June 7, 2024
VIA EDGAR AND FACSIMILE
United States Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F. Street, N.E.
Washington, D.C. 20549
Attention: Tamika Sheppard
Re:
Lexaria Bioscience Corp. (the “Company”)
Registration Statement on Form S-1
File No. 333-279909
Ladies and Gentlemen:
In accordance with Rule 461 under the Securities Act of 1933, as amended, the undersigned respectfully requests that the effective date for the Registration Statement referred to above be accelerated so that it will be declared effective at 4:30PM EDT on Tuesday, June 11, 2024, or as soon thereafter as is practicable.
If you have any questions, please call Avital Perlman at 212-930-9700.
Very truly yours,
LEXARIA BIOSCIENCE CORP.
By:
/s/ Christopher Bunka
Name:
Christopher Bunka
Title:
Chief Executive Officer